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Abstract 
Tuomela, L.A. (2015) Nanocrystals for Drug Delivery Applications 
 
Dissertationes Scholae Doctoralis Ad Sanitatem Investigandam Universitatis 
Helsinkiensis, 28/2015 
 
ISBN 978-951-51-1001-5 (paperback), ISBN 978-951-51-1002-2 (PDF), 
ISSN 2342-3161 (print), ISSN 2342-317X (online)  
 
Low oral bioavailability and general delivery problems related to poorly water 
soluble drugs are major challenges in pharmaceutical formulation development. 
Nanocrystal technologies have been introduced as advantageous, universal 
formulation approaches for these molecules. Nanocrystals, with greater surface to 
volume ratio, can effectively increase both the dissolution rate and saturation 
solubility of active ingredients. 
The aim of this thesis was to obtain detailed knowledge about the dissolution 
characteristics of drug nanocrystals, and to develop feasible nanocrystal applications 
for ocular and oral drug delivery purposes. Hence, develop-ability issues from the 
analytical difficulties of the drug dissolution behavior to the scale-ability of the 
nanocrystals were covered. A new approach in dissolution testing of nanocrystals, 
UV imaging, was introduced and applied for the first time in order to study drug 
dissolution from solid nanocrystal compacts. The focus was detailed understanding 
of the real-time dissolution behavior of different nanosized particle fractions, and the 
possibly generated supersaturated states. Moreover, both liquid and solid nanocrystal 
dosage forms were formulated and studied in vitro and  in vivo.  
High-quality nanocrystal suspensions were successfully prepared using the rapid 
and industrially relevant top-down wet milling technique. Nanocrystal dissolution 
analyses were performed in real-time during the dissolution process, which enabled 
a close level insight into the occurring phenomena. The relevance of the nanosized 
particle fraction was established in these experiments. With regards to the 
formulation development, an in vivo effective nanocrystal suspension formulation 
was developed for ocular delivery, to treat elevated intraocular pressure. 
Furthermore, nanocrystal suspensions were converted into dry powders by both 
freeze-drying and granulating techniques. The dry powders were further processed 
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into tablet and capsule formulations and tested in vitro and in vivo. As a result, the 
great difficulties in predicting the in vivo behavior based on the in vitro results, was 
addressed. Finally, the feasibility parameters for nanocrystal compositions of solid 
formulations at higher scale were optimized by screening powder and tablet 
properties. Hence, optimal compositions for nanocrystalline tablet compositions 
were indicated with regards to the higher scale process-ability. It was concluded that 
the methods applied and studied provided valuable knowledge and important tools 
for the pharmaceutical formulation development in order to solve the current 
problems related to the delivery of poorly soluble drugs.  
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1 Introduction 
Pharmaceutical drug formulation development encounters tremendous problems 
related to poorly soluble compounds. Most of the drugs in the development pipelines 
and drugs coming from synthesisor high throughput screening, i.e. new chemical 
entities,  are poorly soluble in aqueous media, many as well simultaneously in 
organic solvents (Heimbach et al., 2007). Poorly soluble drugs, possessing very 
limited solubility and dissolution velocity, consequently display many 
biopharmaceutical issues in oral drug delivery: low bioavailability, high fasted/fed 
state variation, retarded onset of action, lack of dose proportionality, high 
interpatient variation and local irritation (Gao et al., 2013).  
Novel, advantageous possibilities to improve the bioperformance of poorly 
soluble drug compounds, are offered by the rapidly emerging field of nanoscience, 
and more precisely nanocrystal technology (Jinno et al., 2006;Ige et al., 2013). The 
diminution of the particle size to nanometer range contributes to an increased 
particle surface area and curvature, and thus to enhanced saturation solubility, 
dissolution velocity, and increased adhesiveness to surface/cell membranes and, 
further, acceptable bioavailability after oral administration (Müller et al., 2011a). 
Hence, nanocrystals possess outstanding features enabling to overcome the 
solubility problems of poorly soluble drugs. Nanocrystal formulations provide an 
enhanced bioavailability, high drug load, low incidence of side effects due to the 
excipients, fast onset of action, versatile administration routes (i.e. oral, parenteral, 
ocular, pulmonary and dermal), no fasted/fed state variation, and an overall 
improvement of efficiency and safety. 
Even though the nanocrystals were launched in the 1990s, there exist still a 
limited number of commercially available nanocrystal products, despite the 
promising potential of the technology (Junyaprasert and Morakul, 2015). At present 
the drug nanocrystals are paid a lot of attention as a promising approach due to an 
increasing number of poorly soluble drugs in the drug development process, 
pharmacoeconomic value, straightforward production and safe composition. The 
pharma companies can benefit from the nanocrystal approach also due to the 
possibility of product line extension offered by the regulatory authorities (FDA) for 
the already existing drug formulations (Singare et al., 2010;Raghava Srivalli and 
Mishra, 2014).  
Introduction 
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Various technologies are developed for the production of drug nanocrystals, 
which are roughly divided in top-down, bottom-up and combinatorial techniques. 
The focus of this thesis is in one of the most beneficial and profitable top-down 
technique, rapid wet media milling, producing nanocrystal suspensions. The liquid 
nanocrystal suspensions can be employed as a liquid dosage form or transformed 
into solid dry powders for further production of tablets or capsules. 
The flexibility of both up-scaling and down-scaling offered by nanocrystals, is a 
great advantage during manufacture process (Van Eerdenbrugh et al., 2009b). In this 
emerging reign of nanocrystal technology, increasing resources are applied in the 
development of effective solid nanocrystal formulations. There exists an urge to 
enable a universal shift of the production of the solid nanocrystal formulations from 
laboratory scale to industrially feasible scale. The scale-ability, or up-scaling, is 
essential for the future of the pharmaceutical development by nanocrystals. The 
success of any formulation development depends on its transfer-ability to large scale 
manufacture (Raghava Srivalli and Mishra, 2014). In order for the up-scaling to be 
successful, a detailed characterization of process parameters, design and choice of 
equipment, development of a robust formulation including effective excipients and 
satisfactory stability surveillance results, are all required (Raghava Srivalli and 
Mishra, 2014). 
Nanotechnology is expected to facilitate revolutionary innovations in the fields 
of biomedical sciences, such as drug therapy, diagnostics and imaging. In drug 
delivery and clinical applications nanotechnology is one of the key factors for 
modern drug therapy, now and in the years to come. In this thesis, approaches to 
detailed investigations of dissolution properties and formulation development of 
drug nanocrystals, are taken. It is essential to establish the significance of 
nanocrystal particle size when dealing with particles below one micron. Since the 
smaller the particle size, the more there will be stability issues to be dealt with. 
Which is why in this thesis, a novel dissolution method, UV imaging, was applied 
for the first time to investigate these rapidly dissolving samples. Later on, the 
advantageous characteristics of drug nanocrystals were utilized as both suspension 
and solid dosage forms, and thus provided important information about the 
industrially and therapeutically feasible nanocrystal formulations. 
Literature review 
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2 Review of the literature 
2.1 Pharmaceutical Nanoparticles 
Poorly-water soluble drug compounds comprise in general a significant problem 
in pharmaceutical formulation development. Currently about 40% of the drugs in the 
industries development pipelines, and even up to 60% of the new chemical entities 
are poorly soluble (Gao et al., 2013). Dissolution of the drug from the formulation is 
a requirement for drug absorption (Dressman and Reppas, 2000;Wang and Thanou, 
2010;Gao et al., 2013). Especially in oral drug delivery, which is the major drug 
administration route due to its numerous benefits, dissolution plays an important 
role. This explains the significance of the issues related to poorly soluble drugs, 
which possess limited solubility and dissolution rate, and consequently exhibit 
several biopharmaceutical problems, e.g. low bioavailability, high fed/ fasted 
variation, retarded onset of action, lack of dose proportionality, high interpatient 
variation and local irritation (Gao et al., 2013). Thus, a significant amount of 
attention has been focused on formulation development strategies for the poorly 
soluble drugs, concerning molecules in biopharmaceutics classification system 
(BCS) class II (poorly soluble, permeable) and class IV (poorly soluble, 
impermeable) (Benet et al., 2008;Merisko-Liversidge and Liversidge, 2011). These 
poorly soluble drugs have been sub-classified into two types of molecules: grease 
ball and brick dust compounds (Bergstrom et al., 2007). Grease ball molecules 
represent highly lipophilic compounds (log P > 4, melting points < 200 °C), which 
cannot form bonds with water molecules. Thus, their solubility is limited by the 
solvation process. Whereas, brick dust molecules show lower log P (< 2) values and 
higher melting points (> 200 °C). Their water solubility is restricted due to the 
strong intermolecular bonds within the crystal structure.  
Several techniques have been applied to overcome the solubility problems of 
poorly soluble drugs, such as co-solvents, salt/pro-drug formation, amorphous 
formulations, solubilization, complexation and approaches that employ inclusion of 
solid dispersions (Serajuddin, 1999;Leuner, 2000), cyclodextrins (Davis and 
Brewster, 2004), melt extrusion (Breitenbach, 2002), emulsions (Davis et al., 1987), 
microemulsions (Kawakami et al., 2002), liposomes (Fenske et al., 2008), micellar 
systems (Torchilin, 2012) and soft gelatin capsules including liquid formulations 
Literature review 
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(Gullapalli, 2010). However, as numerous times evidenced, these approaches offer 
no universal solution. Novel possibilities are offered also by the rapidly emerging 
field of nanoscience. Nanotechnology is a broad interdisciplinary area of research, 
development and industrial activity that has been growing rapidly worldwide during 
the past decades (Aitken et al., 2006). The use of reduced particle size approach to 
form stable nanometer size drug formulations has been shown to be an advantageous 
formulation strategy. Nanotechnology can be considered to comprise the areas of 
nanomedicine, nanofabrication, nanometrology and nanomaterials, including 
nanoparticles (Aitken et al., 2006). The concept of nanoparticles covers also 
nanodevice systems, e.g. nanopores, fullerenes, dendrimers, nanotubes, nanowires, 
generally exhibiting particle sizes below 100 nanometers (Aitken et al., 
2006;Longmire et al., 2008;Parveen et al., 2012). 
Formulating poorly-water soluble actives as nanometer-sized drug particles, 
generally referred to as pharmaceutical nanoparticles, have shown great promise in 
terms of biomedical applications, ranging from novel drug delivery platforms and 
drug targeting to diagnostics and tissue engineering. The nanoparticulate systems are 
roughly categorized into matrix nanoparticles, consisting e.g. of a polymeric matrix 
(polymeric nanoparticles (Couvreura et al., 1977) or a lipidic matrix (nanoemulsions 
(Collins-Gold et al., 1990), liposomes (Crommelin and Storm, 2003) and lipid 
nanoparticles (Müller et al., 2011b))), and drug nanocrystals (NCs) (Figure 1). The 
matrix particles have the drug distributed throughout, possibly inside, the matrix 
and/or adsorbed onto their surface (drug loading << 100%), whereas the drug 
nanocrystals consist of 100% drug, typically stabilized by surfactants or polymeric 
steric stabilizers [1,2]. High drug loading of NCs makes them very efficient in 
transporting the drug to or in the cells, reaching a sufficiently high therapeutic 
concentration for the pharmacological effect. Often drug NCs are referred to as drug 
nanoparticles, which might lead to confusion with polymeric nanoparticles. The NCs 
are typically produced in a liquid dispersion medium, which contains stabilizers for 
the colloidal state; therefore these systems can also be referred to as nanocrystal 
suspensions (NPS). In the field of pharmacy the definition of NCs covers particles 
below one micron (Merisko-Liversidge et al., 2003;Gao et al., 2013), however the 
NCs in the size range between 100 nm and <1000 nm may sometimes be more 
suitably classified as submicron particles (Müller et al., 2011a). In order to give 
some idea about the size scale, bulk drug materials possess typically particle sizes of 
tens to hundreds of microns, i.e. indomethacin ~ 80 µm, whereas micronized drug 
Literature review 
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particles are around tens of microns. In this thesis, the particles below one micron 
are referred to as NCs. 
 
Figure 1 Pharmaceutical nanoparticles and their structural arrangement with 
emphasis on drug distribution: matrix particles, including polymeric nanoparticles 
(A), nanoemulsions (B), solid lipid nanoparticles (SLN) and nanostructured lipid 
carriers (NLC) (both derived from C), versus drug nanocrystals (NC) (D) (modified 
after Müller et al., 2011a;Pawar et al., 2014). 
2.2 Nanocrystals (NCs) of poorly water soluble drugs 
Novel advantageous possibilities for pharmaceutical research are offered by the 
rapidly emerging field of drug nanocrystal technology, the major contributions of 
which are the benefits for formulating poorly soluble drugs (Rabinow, 2004). The 
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special characteristics of drug NCs are discussed here in detail, followed by the 
nanocrystallization methods and the analytical specificities of NCs.  
2.2.1 Special features of NCs 
The dissolution rate of a drug is of special importance when it is the rate-limiting 
step for the uptake of drugs after oral administration. This is the case for many 
hydrophobic, especially BCS class II, drugs with extremely low aqueous solubility. 
Basically, the solubility is considered low if the highest dose solubility volume is 
more than 250 ml. Drug with poor solubility and dissolution rate will provide a slow 
and erratic dissolution that limits the in vivo absorption and achievement of an 
effective therapeutic concentration. Therefore, investigations of different ways to 
enhance the dissolution of these drugs are of special interest. Compared to the 
micron-sized drug powders the special features of NCs display a series of benefits 
on the bioperformance of the poorly soluble drugs, including improved absorption, 
enhanced bioavailability, rapid onset of action, reduced fed/fasted state variability, 
reduced intersubject variability and ability for dose escalation and hence improved 
efficacy and safety (Shegokar and Müller, 2010;Merisko-Liversidge and Liversidge, 
2011). The mechanisms contributing for the enhanced oral bioavailability of drug 
NCs are based on enhanced bioadhesion to the surfaces/cell membranes, and most 
importantly on increased saturation solubility and dissolution velocity, which lead to 
high drug concentration gradient between gastrointestinal tract and blood vessel, and 
thus contribute to improved absorption and high bioavailability (Müller et al., 
2011a). Furthermore, besides for the improvement of the dissolution features of 
poorly soluble molecules, due to their simple structure and versatile features the NCs 
can also be utilized in controlled and targeted drug delivery for example by surface 
modification. 
2.2.1.1 Enhanced oral bioavailability 
The essence of nanosizing poorly water soluble compounds rests primarily in the 
Noyes-Whitney and Prandtl equations, which describe how the reduction of the 
particle size facilitates an increase of the surface area and a decrease of the diffusion 
layer thickness, and thus provide an enhanced dissolution rate (Noyes and Whitney, 
Literature review 
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1897;Prandtl, 1904;Mosharraf and Nyström, 1995;Hörter and Dressman, 
2001;Kesisoglou and Mitra, 2012). Whereas the enhancement in saturation solubility 
with nanosized particles is described by the Ostwald–Freundlich and Kelvin 
equations, which correlate particle size and particle curvature with solubility (von 
Helmholtz, 1886;Noyes and Whitney, 1897;Wu and Nancollas, 1998;Godec et al., 
2009;Kesisoglou and Mitra, 2012). Thus, with particles below one micron, the 
saturation solubility depends not only on the drug compound, the dissolution 
medium and temperature but also on the particle size (Junghanns and Müller, 
2008).The special features of the NCs are summarized in Figure 2. 
According to the Noyes–Whitney equation (Figure 2) the dissolution velocity 
(dc/dt) is determined by the rate of change of mass dissolved with time (t), related to 
the diffusion coefficient (D) through a static layer of liquid of thickness h, and Cs, 
the equilibrium solubility (the concentration of the solute required to saturate the 
solvent) and the amount dissolved in the bulk medium at time t (Ct) (Buckton and 
Beezer, 1992). The concentration around the particles at time t (Ct), can be 
influenced by a changing particle size. According to the equation an increase in the 
surface area (A) of a drug will result in a more rapid dissolution process, particularly 
under sink conditions (C<<<Cs). According to Prandtl boundary layer equation (k 
denotes a constant): 
 
              ⁄  (1) 
 
in dispersed solid-liquid systems, particle size reduction results in an increase of 
the dissolution rate of a sparingly soluble material by decreasing the thickness of the 
diffusion layer (h) around each particle (Prandtl, 1904;Mosharraf and Nyström, 
1995). When the h decreases, both the Cs and the concentration gradient ((Cs-Ct)/h) 
will increase and hence the dissolution rate will increase according to Noyes-
Whitney. Basically, according to Prandtl, a decrease in particle size leads to a 
decrease in both the length of the surface in the direction of flow (L) and in the 
relative velocity of the flowing liquid surrounding the particles parameters (V), 
where the net effect is a thinner diffusion layer (h) around the particles and an 
increase in the surface specific dissolution rate (Bisrat and Nyström, 1988). 
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Figure 2 Special features of nanocrystals: (1) increased saturation solubility (Cs) 
due to the increased dissolution pressure of strongly curved small NCs, (2) 
increased dissolution velocity (dc/dt) due to increased surface area (A) and 
decreased diffusional distance (h) and (3) increased adhesiveness of NCs due to the 
increased contact area (modified after Mauludin et al., 2009;Müller et al., 2011a). 
With submicron particles, saturation solubility is a function of particle size: the 
saturation solubility increases with the decreasing particle size. This is based on an 
increase in the curvature of the particle surface, and thus enhanced dissolution 
pressure (Figure 2). The phenomenon can be explained by the Kelvin (Eq. 2) and the 
Literature review 
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Ostwald–Freundlich (Eq. 3) equations (von Helmholtz, 1886;Wu and Nancollas, 
1998;Mauludin et al., 2009;Müller et al., 2011a). Initially the Kelvin equation 
defines the vapor pressure over a curved surface of a liquid droplet in gas phase 
(Thomson, 1871;Junghanns and Müller, 2008;Junyaprasert and Morakul, 2015); A 
decline in the particle size of liquid droplet provides an increase in curvature of the 
surface and the increasing vapor pressure. The transfer of molecules from a liquid 
phase (droplet) to a gas phase is in principle identical to the transfer of molecules 
from a solid phase (nanocrystal) to a liquid phase (dispersion medium). Thus, the 
vapor pressure is considered equivalent to the dissolution pressure. Therefore, the 
Kelvin equation is also applicable to explain the relationship between the dissolution 
pressure and the curvature of the solid particles in liquid (von Helmholtz, 1886;Wu 
and Nancollas, 1998;Junyaprasert and Morakul, 2015): 
 
  
 
  
 
    
   
   (2) 
  
where Pr is the dissolution (vapor) pressure of a particle with the radius r, P0 is 
the saturated dissolution pressure of the surrounding medium or flat surface, γ is the 
surface tension, Vm is the molecular volume of the solute particle, R is the gas 
constant, T is the absolute temperature and r is the radius of the particle. In a 
saturated solution, there exists an equilibrium between dissolving and recrystallizing 
molecules. The equilibrium is transferred when the dissolution pressure increases 
(decreasing particle size), and thus the saturation solubility increases. Additionally, 
the Ostwald–Freundlich equation, which is an equivalent to the Kelvin equation, 
precisely expresses the relationship between the saturation solubility and the particle 
size (von Helmholtz, 1886;Wu and Nancollas, 1998;Junyaprasert and Morakul, 
2015): 
 
  
 
  
 
    
   
  (3) 
  
where S is the saturation solubility, S0 is the solubility of the solid consisting of 
large particles, γ is the interfacial tension of substance, Vm is the molar volume of the 
particle material, R is the gas constant, T is the absolute temperature and r is the 
radius. From the Ostwald–Freundlich equation, it is clearly shown that the saturation 
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solubility (S) of a drug increases with a decrease in the particle size (r). However, 
this effect is pronounced solely for submicron particles. 
Drug NCs possess also an outstanding feature of distinctly increasing 
adhesiveness to biological mucosa including gastrointestinal (GI) mucosa (Figure 2) 
(Ponchel et al., 1997;Junyaprasert and Morakul, 2015). The increased adhesiveness 
is usually due to an increased contact area of NCs, which lead to an improvement of 
oral absorption of poorly soluble drugs apart from the increased saturation solubility 
and dissolution rate (Möschwitzer and Müller, 2007;Gao et al., 2012). For NCs, the 
mucous gel layer is a porous structure, into which they can quickly and deeply 
penetrate and reach a close contact with the mucous network. Also, the adsorption 
isotherm shows linear increase with particle concentration (Ponchel et al., 1997). 
Different theories of mucoadhesion mechanisms of nanoparticles have been 
proposed (Gao et al., 2013): the electronic theory (electrostatic attraction forces 
between the surfaces of particles and mucus), the adsorption  theory (secondary 
forces such as hydrogen and van der Waals bonds between the surfaces of particles 
and mucus), the diffusion theory (interpenetration and physical entanglement of the 
protein of the mucus and polymer chains) and the trapping theory (retention of 
nanoparticles by the uneven mucosa surface). The GI mucoadhesion of drugs 
enables the drug release exactly at the absorption sites, which leads to a high 
concentration gradient and prolonged retention time (Li et al., 2009). In order to 
strengthen the mucoadhesion, further processing, e.g. incorporation of 
mucoadhesive polymer or surface modification with cationic polymers, which 
facilitate stronger adhesiveness to the negative mucin of the mucosal surface, can be 
performed (Kayser, 2001). 
Another factor affecting the dissolution behavior of drugs is the crystalline state. 
Depending on the preparation process of drug NCs, it may induce the transformation 
of crystalline structure, increase an amorphous fraction or even create completely 
amorphous particles. Compared to equally sized drug NCs in the crystalline form, 
drugs in the amorphous state possess higher solubility and faster dissolution rate due 
to the higher inner energy (Sarkari et al., 2002;Gao et al., 2011). However, the 
utilization of the amorphous state in pharmaceutical products has to be carefully 
considered that it can maintain the amorphous state for the shelf life of the product 
(Junghanns and Müller, 2008;Van Eerdenbrugh et al., 2009a). Thus, although 
conversion to the amorphous state can markedly improve solubility and dissolution 
characteristics, the amorphous state may revert to a lower energy state, typically 
crystalline form during storage. Unfortunately the behavior of such conversions is 
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not easy to predict, and thus NC at crystalline state are mainly preferred (Vogt et al., 
2008). 
Despite these advantageous features of NCs, the greatest challenge arises 
however along the small particle size. The nanosize induces physical stability 
problems presented more in detail in the following chapter. 
2.2.1.2 Stability 
Since the preparation of NC suspensions generates an increase in the particle 
surface area and hence, the surface interactions, they have an extremely high 
tendency to aggregate. Due to the increased Gibbs free energy in the system, 
associated with the formation of additional interfaces, the NC suspensions as 
colloidal systems exhibit thermodynamically unstable states and have a tendency to 
minimize the total free energy by agglomeration/aggregation (Van Eerdenbrugh et 
al., 2008). Thus, the long-term stability of NC formulations is strongly affected by 
the particle aggregation, which mostly depends on the stabilizer, its type and 
concentration used (Sinha et al., 2013). Still, the long-term stability is considered a 
special feature of drug nanocrystals (Junyaprasert and Morakul, 2015). The NC 
suspension can show good physical stability by an absence of aggregation and 
Ostwald ripening phenomenon. 
Kinetically, the aggregation process depends on its activation energy, which can 
be increased by including stabilizers to the system (Van Eerdenbrugh et al., 2008). 
The appropriate stabilizer provides thus a barrier to aggregation. Theoretically, the 
principle of an energetic barrier can be explained by the DLVO theory, according to 
Russians Deryagin and Landau and the Dutch scientists Verwey and Overbeek. The 
theory basically describes the interaction of solid particles in a liquid medium in 
terms of attractive and repulsive interactions between the electric double layers 
surrounding the particles in solution (Derjaguin and Landau, 1993;Van Eerdenbrugh 
et al., 2008). The balance between the attractive and repulsive forces is adjusted by 
the stabilizers in the nanocrystalline systems. Additionally, the kinetic stability of a 
suspension may also be controlled by some surface forces, such as hydrophobic 
forces. 
The Ostwald ripening phenomena (Jacobs et al., 2000;Müller et al., 2001) has 
been described for highly dispersed systems, and means a reduction in size of the 
finest particles fraction and the final disappearance combined with simultaneously 
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growth of larger particles. Reasons for the phenomena are the different saturation 
solubilities in the vicinity of differently sized particles and the concentration 
gradient existing between them. The molecules surrounding the small particles will 
diffuse to surround the large particles driven by the concentration gradient. Due to 
the supersaturation, recrystallization occurs on the surface of the larger particles 
leading to the formation of microparticles. Simultaneously the concentration in the 
vicinity of the smaller particles will decrease below the saturation concentration, 
thus leading to further drug dissolution, and the fine particles getting even smaller. 
This continuous process leads finally to the disappearance of the fine particles. Due 
to the uniform particle size of NCs, created by the homogenization process, the 
difference in saturation solubility due to different particle sizes and thus, an absence 
of Ostwald ripening phenomena, can be avoided. Additionally, the stabilizer layer 
surrounding the particles also prevents Ostwald ripening.  
The stabilization is based on the stabilizer absorption on the particle surfaces in 
order to decrease the free energy of system and the interfacial tension of particles. 
The principle mechanisms consist of electrostatic and steric stabilization. The 
selection of the suitable type of stabilizer and its optimal concentration are very 
important for stabilizing the smaller sized particles and to maintain the shelf life 
stability of the final product (Van Eerdenbrugh et al., 2009a). The stabilizer used 
may be: (1) semisynthetic non-ionic polymers (HPMC, MC, HEC, HPC) (Choi et 
al., 2005;Zuo et al., 2013;Tuomela et al., 2014), (2) semisynthetic ionic polymers 
(NaCMC, NaAlg) (Sinha et al., 2013), (3) synthetic linear polymer (PVPs, PVAs) 
(Ghosh et al., 2013), (4) synthetic copolymers (poloxamers, polyvinyl alcohol–
polyethylene glycol graft copolymer) (Liu et al., 2011;Kumar et al., 2014), (5) 
surfactant of ionic type (SDS, sodium docusate, sodium deoxy cholate), or (6) non-
ionic type surfactant (polysorbate esters, sorbitan esters) (Sinha et al., 2013). 
Additionally, for instance an application of a combination of ionic surfactants with 
polymeric stabilizers may provide an enhanced stabilization which combines the 
advantages of both the electrostatic and steric stabilization. So far, the selection of 
suitable stabilizer for nanocrystallization has been mostly based on trial and error. 
However, recently surface plasmon resonance (SPR) and contact angle techniques 
were successfully applied as tools for monitoring stabilizer-drug interactions for 
nanocrystal research (Liu et al., 2015). Three fundamental requirements for efficient 
stabilizer were concluded: firm attachment to the solid surface, coverage of the 
nanocrystal and the hydrophilic/lipophilic balance of the stabilizer structure.  
Besides the physical stability, drug NC can be used for a chemical stabilization of 
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chemically labile drug (Junyaprasert and Morakul, 2015). The increased stability of 
drug NCs can be explained by a shield effect of surfactants and a monolayer of 
degraded drug molecules, which act as the surface of drug NCs for protecting the 
drug underneath its surface from degradation. 
Despite the generally straightforward and yet safe compositions of drug NCs, 
similarly with any drug formulations, the possible toxic effects have to be still 
carefully considered. This aspect is covered in the following section. 
2.2.1.3 Toxicity of NCs 
Nanomaterials, including NCs, often behave differently from their bulk 
counterparts. The possible magnetic, optical and complicated structural properties 
make a direct transition of the understanding about bulk toxicity impossible to the 
corresponding nanomaterial. Thus, the determination of the safety of nanomaterials 
is a difficult and ever ongoing process. Besides the size factor, there exist a number 
of parameters contributing to the possible toxic effect that should be considered; 
surface area, surface charge, chemical composition and reactivity, solubility, shape 
and agglomeration potential (Oberdorster et al., 2005a). Nanomaterials enter the 
body via various traditional routes (orally, through the respiratory system, through 
blood circulation, through the skin), through which they can interact with the body 
greatly differently than their corresponding micronsized versions (Oberdorster et al., 
2005b;Leslie-Pelecky, 2007). The nanoscale materials can penetrate deeper into the 
tissues than larger particles. They have the potential to produce oxidative stress, 
inhibit cell proliferation, reduce phagocytosis and decrease cell viability (Leslie-
Pelecky, 2007). Nanoparticles can also remain in the body longer, due to the ability 
to escape the reticuloendothelial system. These effects are the stronger the smaller 
the particles are in question. 
Despite that, NCs with the size in the range of about 100-1000 nm can only be 
taken up by a limited number of cells with phagocytic activity, e.g. the macrophages 
of the mononuclear phagocytic system (MPS), which are not easy to access (Müller 
et al., 2011b). This is different for particles with a size below 100 nm. These 
particles can be taken up by all cells by endocytosis. Therefore, they can be 
considered as high risk nanoparticles. A nanotoxicological classification system 
(NCS) is applied to assess the toxicity risk of nanoparticles (Müller et al., 2011a). 
The size and biopersistency related risks are combined to classify the nanoparticles 
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according to the toxicity risk as follows: class I (nanoparticles >100 nm and 
biodegradable), class II (nanoparticles >100 nm and non-biodegradable), class III 
(nanoparticles <100 nm and biodegradable), and class IV (nanoparticles <100 nm 
and non-biodegradable). The NCs are a priori low risk or non-risk nanoparticles, due 
to their particle size (generally > 100 nm) and biodegradable nature (dissolution 
occurs in sufficient water amount). Consequently, the toxic risk of NCs is limited. 
However, NCs may cause undesired systemic effects in the body or intracellularily 
until the complete dissolution, which is generally not an issue because of the rapid 
dissolution behavior of NCs. In case NCs significantly improve the bioavailabity, 
the therapeutic dose has to be reconsidered in order to avoid toxicity caused by 
overdosing. Thus, the development of NCs requires the detailed investigation in 
order to facilitate the potential effects with low toxicity, even with biodegradable 
nanoparticles. 
Generally drug nanocrystals are reported safe and well tolerated in many 
administration routes compared with the conventional products (Junyaprasert and 
Morakul, 2015). The toxicity of the material is mostly the issue, not the toxicity of 
the NCs.  
2.2.2 Methods for nanocrystallization 
Drug nanocrystals are commonly prepared in a liquid dispersion medium 
producing nanocrystal suspensions (NPS) (Müller et al., 2011b). The 
nanocrystallization techniques are mainly divided into bottom-up and top-down 
approaches (Figure 3). Additionally, there exist combinations of the previous. 
The top-down nanocrystallization approaches are high energy processes, 
comprising wet media milling and high-pressure homogenization (HPH), where 
micronsized drug crystals are diminished to nanodimension under mechanical 
attrition or high pressure, respectively. In the wet media milling method the drug 
particles are dispersed in a surfactant/stabilizer solution and the obtained 
microsuspension is then subjected to milling energy (Müller et al., 2011a). The 
particle size is reduced by the shear forces generated by the movement of the milling 
media. The crystals are ground between the moving pearls, moved by an agitator, 
resulting in a NPS. Generally, after wet media milling process crystalline structures 
have been reported (Müller et al., 2001;Liu et al., 2011). During wet milling of 
crystalline drugs the water is acting as an inhibitor of the formation of amorphous 
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material due to the reduced glass-transition temperature (Sharma et al., 2009). 
Different sized milling pearls of zirconium dioxide, stainless steel, glass or highly 
crosslinked polystyrene resin-coated beads may be used. The erosion from the 
milling material during the process may be a problem of this technology. The 
milling time varies from minutes to hours or days, according to the hardness of the 
drug, viscosity, temperature, energy input, size of the milling medium and surfactant 
concentration used (Shegokar and Müller, 2010;Müller et al., 2011a). Wet milling is 
considered as a standard method to produce NPS and as a platform technology for 
formulating poorly soluble compounds. Generally, the brick dust molecules, which 
are not only poorly soluble in water, but also in oils, have shown to benefit from the 
development of NPS and amorphous systems (Bergstrom et al., 2007;Pu et al., 
2009). Thus, they are considered suitable substances for milling. Whereas, the oral 
bioavailability of grease ball molecules can be increased, for instance, by the 
inclusion into cyclodextrines, application of micelles and lipid-based formulations. 
Thus, milling is most likely not the effective method to be applied for the grease ball 
molecules. 
 The versatility of the technique and the achievable particle sizes are the most 
important aspects for the success of this technology. The reported particle sizes of 
the various APIs illustrate the universal applicability of this particle size reduction 
method. 
High pressure homogenization (HPH) can be regarded as the second most 
important technique to produce drug NPS (Möschwitzer, 2013). For HPH there exist 
three basic processes: 1) the jet stream principle (Microfluidizer, IDD-P
TM
 (insoluble 
drug delivery microparticle technology) (Keck and Müller, 2006), where high 
energy fluid streams of the suspension collide, 2) the piston-gap homogenization 
either in water (Dissocubes® technology,) (Müller et al., 2003), or  3) alternatively 
in water-reduced/non-aqueous media (Nanopure® technology), in which a 
drug/surfactant microsuspension is forced with a high velocity by a piston under 
pressure (Radtke and Müller, 2001;Shegokar and Müller, 2010). HPH techniques 
usually promote the formation of amorphous state, which may be prone for 
recrystallization (Müller et al., 2001). However, this is dependent on the process 
parameters and conditions used. The obtained solid state has been reported to be 
strongly affected by the presence of water (Sharma et al., 2009). The role of water in 
inhibiting the amorphization during HPH of crystalline drugs was significant. 
The bottom-up approaches are generally based on the drug precipitation from a 
supersaturated solution of the drug. These precipitation approaches can be 
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categorized in four groups: precipitation by liquid solvent-antisolvent addition, 
precipitation in the presence of supercritical fluid, precipitation by the removal of 
solvent and precipitation in the presence of high energy processes (Sinha et al., 
2013). The precipitation based methods have commonly the potential to produce 
amorphous material (Sinha et al., 2013). However, the amorphous form may be 
converted to crystalline state in the presence of water. Recrystallization is a common 
phenomenon with amorphous material. 
 
 
 
Figure 3 The basic principle of nanocrystallization techniques (modified after 
Rabinow, 2004). 
Combination of the bottom-up and/or top-down approaches provides an effective 
method to produce smaller particle sizes and also to overcome the deficiencies of the 
techniques, i.e. clogging of the equipment and relatively long process times. 
Basically the combination methods consist of a pre-treatment step followed by a 
high energy top-down process. The first combinative method, Nanoedge
TM
 
technology, consists of a classical micro-precipitation pre-phase followed by HPH 
(Möschwitzer, 2013). Usually, the second phase inhibits further crystal growth and 
aggregation after precipitation, and converts the amorphous and semi-unstable 
crystalline form arising from precipitation process to the crystalline form. However, 
this is not necessarily always the case.  
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Later on, the SmartCrystal® technology presents a series of combination 
approaches. SmartCrystal® technology combines the pre-treatment and subsequent 
main treatment (HPH) (Shegokar and Müller, 2010). The methods comprise of the 
following pre-treatment techniques combined with the HPH: Nanopure (no pre-
treatmeant), H42 (spray-drying), H69 (precipitation), H96 (lyophilization) and CT 
(media milling) (Shegokar and Müller, 2010). Even though the combination 
technologies improve the particle size reduction and the effectiveness of the process, 
the fact is that any pre-treatment step increases the complexity of the overall process 
and can significantly increase the costs. Therefore it is obvious that combinative 
particle size reduction methods will be only used in cases that the more established 
methods, like wet ball milling or standard high pressure homogenization, cannot be 
used to reach the desired results (Möschwitzer, 2013). 
When considering the final formulations of drug NCs, solid dosage form is 
usually the preferred. Therefore, the NPS are converted into dry powders, which are 
further processed into tablets, capsules, or pellets. 
2.2.3 Conversion into solid form 
Different drying and granulation methods are mainly utilized to convert the 
aqueous NPS into dry powders. Firstly, the aqueous NPS can be powdered through 
some drying processes, such as the lyophilisation (i.e. freeze-drying), spray drying 
or oven drying (Badawi et al., 2011;Lai et al., 2011). The resultant powders, blended 
with other excipients, are further processed into solid dosage forms through shaping 
and handling, such as direct compression and capsule filling (Mauludin et al., 
2009;Juhnke et al., 2012). Spray-drying process is the cost effective approach to 
transform the NPS into dry powders under appropriate conditions. Freeze-drying is 
recommended for e.g. intravenous products in order to avoid aggregation or caking 
of the settled drug NCs. Particle aggregation should be inhibited during the drying 
process since the benefits of NCs will be lost if aggregation occurs. Therefore, an 
addition of lyoprotectants (usually sugars) may reduce the growth of particle size 
during the solidification process. However, often the stabilizer alone provides 
adequate protection against the aggregation during freeze-drying.  
 Secondly, a granulation method may be used for solidification. The aqueous 
NPS is used as granulation fluid in the granulation process or as layering dispersion 
in a fluidized bed process (Kocbek et al., 2006;Basa et al., 2008). Independent of the 
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chosen solidification technology, aggregation of the drug nanoparticles is a 
phenomenon that has been reported to be able to profoundly impact the properties of 
products intended for a diversity of applications (Figure 4) (Wang et al., 2005b). If 
irreversible aggregation takes place, the gained profits of large surface of the 
original nanosized particles would be greatly jeopardized since the surface area 
advantage of NCs would be lost. Additionally, the redispersion of solid drug NCs in 
the GI fluids should be concerned (Junyaprasert and Morakul, 2015). The stabilizers 
attached to the NC surfaces that provide efficient ionic or steric repulsion and have 
no effect from the GIT environment should be used. However, generally the steric 
stabilization is the most common mechanism with the NCs stabilized with non-ionic 
stabilizers such as poloxamers. 
 
 
 
Figure 4 The solidification of NC suspensions is aimed to facilitate reversible 
aggregation of dry powders, which thus rapidly reconstitute into the individual NCs 
when dispersed in an aqueous medium (modified after Gao et al., 2013). 
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2.2.4 Dissolution testing 
The determination of a dissolution profile of any drug formulation/compound is 
a prerequisite for the investigation of the drug release and absorption behavior. 
Moreover, it is the most important primary evidence about the profitable nature of 
NCs of poorly soluble drugs. Dissolution studies are widely utilized in 
pharmaceutical formulation development processes, ranging from the 
characterization of API until the prediction of the in vivo performance of the 
compound/formulation (Tong et al., 2009). Especially the dissolution study is 
essential in showing the bioequivalency between formulations, (Amidon et al., 
1995). An optimized, possibly differentiating, experimental set-up is desired in 
general for dissolution studies (Nikolic et al., 1992). The experimental conditions 
may have a drug release regulating effect. Thus, careful consideration should be 
made in the selection of e.g. dissolution medium, pH of the medium, volume of the 
medium and prevailing temperature. 
When considering the existing traditional, oftentimes material and time 
consuming, pharmacopoeial dissolution methods (USP, European and Japanese 
Pharmacopoeia) that are mainly developed for quality control purposes, they are 
often regarded inadequate and not evolved enough to correspond to the needs of 
modern dissolution studies, i.e. to study in detail rapidly dissolving samples like 
NCs (Dokoumetzidis and Macheras, 2006;McAllister, 2010). The traditional 
methods, e.g. paddle (USP II) method combined with UV spectroscopy or HPLC, do 
not provide real-time, spatially and temporally resolved information of the 
dissolution process, since the monitoring of the process immediately next to the 
surface of the dosage form is impossible with those techniques (Windbergs et al., 
2009;Greco and Bogner, 2012). Despite that, they are still valid methods to explore, 
compare and obtain information about dissolution behavior of different 
compounds/formulations, including nanocrystalline samples, both suspensions and 
solid formulations. In addition to the traditional methods, today there exist several 
methods to study the dissolution of solid dosage forms, which are based on imaging, 
e.g., UV, FT-IR, NIR, and MRI imaging, CARS and Raman spectroscopy, in order 
to cover those missing aspects of traditional methods (van der Weerd and Kazarian, 
2005;Aaltonen et al., 2006;Kazarian and van der Weerd, 2008;Metz and Mader, 
2008;Nott, 2010;Østergaard et al., 2010;Kowalczuk and Tritt-Goc, 2011). 
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2.3 Applications of NCs 
There exist several subjects within the field of pharmaceutical drug delivery, 
which can greatly benefit from the NC approach. Hence, the wide suitability of NCs 
to different administration routes and biomedical applications are here presented, 
followed by the examples of the currently marketed NC products.  
2.3.1 Delivery routes of NCs 
2.3.1.1 Oral delivery 
NCs are studied mainly through oral, ocular, pulmonary, parenteral, and dermal 
routes, all showing their high therapeutic applicability (Pawar et al., 2014). Due to 
the several advantages, the oral route is the most preferred and is considered as the 
safest and most suitable route for drug delivery. NCs offer solutions to the solubility 
related problems, such as low/variable bioavailability, a retarded onset of action, a 
variation in bioavailability resulting from fed/fast state and a large oral dose usage. 
NCs facilitate an increased dissolution rate, higher saturation solubility (Noyes-
Whitney and Ostwald-Freundlich principles) and bioadhesion to the intestinal wall, 
thus impressively improving the bioavailability of orally administered poorly 
soluble drugs. This is shown as changes in pharmacokinetic parameters of blood 
profiles, including an increase in area under the blood concentration-time curve 
(AUC), an increase in maximum plasma concentration (Cmax) and a decrease in 
time to reach maximum plasma concentration (Tmax), describing quick onset of 
action (Liversidge and Conzentino, 1995;Xia et al., 2010;Li et al., 2011). For 
instance, a 16-fold increase in bioavailability of danazol, together with reduced 
Tmax and 15-fold increase in Cmax, were obtained by the conversion of the 
micronsized particles into NCs (Liversidge and Cundy, 1995).  
Poorly soluble drugs often exhibit increased or accelerated absorption when they 
are administered with food, due to the enhancement of the dissolution rate in the 
GIT caused by factors such as delayed gastric emptying, increased bile secretion, 
larger volume of the gastric fluid, increased gastric pH (for acidic drugs) and 
increased splanchnic blood flow (Jinno et al., 2006). Also, the fat within the food 
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itself may act as dissolving agent. Applying NPS the variation in bioavailability 
resulting from fasted/fed state can be minimized (Gao et al., 2013;Junyaprasert and 
Morakul, 2015). The reason is that the dissolution rate of NCs is fast enough even 
under the fasted condition. Therefore, the absorption in both fasted and fed state can 
be a permeability-limited process, and the absorption difference between the fasted 
and fed conditions due to the dissolution difference is eliminated (Figure 5). 
 
 
 
Figure 5 The fasted/fed state variation of drug NCs is reduced due to their rapid 
dissolution (modified after Merisko-Liversidge et al., 2003;Gao et al., 2013). With 
NCs permeation might be the limiting factor for drug absorption. 
 
Due to the fine particle sizes of the NCs, the distribution uniformity in the GI 
fluid is enhanced and high, and prolonged local concentrations are avoided 
(Liversidge and Conzentino, 1995). Thus, NCs are also better tolerated in the 
mucosal delivery by reduced gastric irritancy.  Finally, the NCs offer an opportunity 
to escalate dose and reduce solvent-related adverse effects due to the safe 
compositions, since no organic solvents or extreme pH ranges for solubilization of 
poorly soluble drug are required (Merisko-Liversidge and Liversidge, 2011). 
Moreover, fine particle size and safe composition are beneficial safety aspects 
for orally delivered NCs. Additionally, the tolerance of NCs to various sterilizations 
provide important benefits regarding other delivery routes where sterility is a 
prerequisite. Various sterilization approaches (Konan et al., 2002;Rabinow, 2004) 
Literature review 
 
 
 
22 
 
can be applied to NC suspensions, including gamma radiation (Junyaprasert and 
Morakul, 2015), filtration sterilization (Zheng and Bosch, 1997) and thermal 
sterilization  (Na et al., 1999). Besides oral drug delivery, also other administration 
routes are often required. The special aspects of parenteral, ocular, pulmonary and 
dermal delivery are reviewed subsequently. 
2.3.1.2 Parenteral delivery 
Subsequently, intravenous (i.v.) administration of poorly soluble compounds, 
using i.e. cosolvents, surfactants, liposomes, or cylcodextrines, is often associated 
with large injection volumes or toxic side effects. Carrier-free NPS empower high 
loading capacity compared to other parenteral application systems. Applying NPS 
the administration volume can be clearly reduced compared to micro-solutions 
(Möschwitzer et al., 2004). Due to the small particle size and safe composition of 
NCs, NPS can be i.v. injected to give 100% bioavailability, immediate action and 
reduced dosing (Müller and Keck, 2004;Ganta et al., 2009;Pawar et al., 2014). NPS 
may also show passive targeting similar to colloidal drug carriers after i.v. 
administration (Peters et al., 2000). Furthermore, also special targeting can be 
achieved by a surface modification using the concept of differential protein 
adsorption. When considering the parenteral administration route, it must be kept in 
mind that the carrier system shall not be phagocytosed by reticuloendothelial 
system. Thus, the size of parenteral NCs should be ≤100 nm (Jinno et al., 2006). 
Additionally, in order to avoid the rapid removal of the NCs and/or nanocarriers 
from the circulation and to endow nanosystems with long circulation properties, the 
long circulating nanocarriers, “stealth” systems, have been introduced (Salmaso and 
Caliceti, 2013). Stealth particles can be obtained by surface coating with hydrophilic 
polymers, thus preventing the opsonisation process (Moghimi et al., 1993;Moghimi 
et al., 2001). Typically stealth approach is applied to liposome systems. However, 
NC surface can also be modified analogue to the stealth liposomes generating stealth 
NCs (Gao et al., 2008). The consequence of avoiding opsonisation is the 
prolongation and permanence in the bloodstream from few seconds to several hours. 
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2.3.1.3 Ocular, pulmonary and dermal delivery 
Ophthalmic drug delivery is a challenging task due to the critical 
pharmacokinetic environment and physiological barriers of the eye hindering the 
delivery of drugs (Geroski and Edelhauser, 2000;Duvvuri et al., 2003;Koevary, 
2003;Dey and Mitra, 2005;Thakur and Kashiv, 2011). Topical instillation is by far 
the most widely preferred, noninvasive route of drug administration to treat diseases 
affecting the anterior segment of the eye (Tangri and Khurana, 2011). Numerous 
anatomical and physiological constraints such as rapid precorneal drug elimination, 
tear turnover, nasolachrymal drainage, reflex blinking, systemic absorption from the 
conjunctival sac and ocular static and dynamic barriers pose a challenge and impede 
deeper ocular drug permeation (Figure 6a) [3]. Hence, less than 5% of topically 
applied dose reaches to intraocular tissues [4] (Urtti et al., 1990;Keister et al., 
1991;Kaur and Kanwar, 2002).  
To overcome the ocular drug delivery barriers and improve ocular 
bioavailability, various conventional (e.g. emulsions, ointments, suspensions, gels) 
and novel, especially nanotechnology based drug delivery systems, e.g. 
nanomicelles, nanoparticles, liposomes, dendrimers, implants, contact lenses, in-situ 
thermosensitive gelling systems and microneedles, have been developed for the 
earlier mention ocular diseases (Ali et al., 2011;Patel et al., 2013). Additionally, for 
instance, by increasing the viscosity and mucoadhesivity of the system, the residence 
time on the mucosa can be prolonged and sustained drug release obtained (Kaur and 
Kanwar, 2002). Furthermore, the pH of eye drops can be adjusted, approx. pH 3–10, 
to maximize the unionized fraction of the drug in order to optimize its ocular 
absorption (Alcon Laboratories, 2004;Gibson, 2009;Wu et al., 2013). Subsequently, 
nanocrystal technology plays an advanced role in ophthalmic drug delivery by 
solving dispersibility issues of poorly soluble drugs, such as budesonide, 
dexamethasone, hydrocortisone, prednisolone (Kassem et al., 2007) [17] and 
fluorometholone (Gupta et al., 2010). The development of such colloidal delivery 
systems for ophthalmic use aims at droppable dosage forms with a high drug 
loading, improved bioavailability and an extended, long-lasting drug action, when 
compared to micronsized bulk material (Ali et al., 2011). The significance of both 
the nanosized particles and the properties of topical nanocrystal suspensions, such as 
the absence of irritation due to the small size, proper viscosity and mucoadhesivity, 
have been well documented in terms of improved ocular bioavailability (Hui and 
Robinson, 1986;Kassem et al., 2007). In addition, the use polymeric nanoparticle 
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suspensions, loaded with the salt form of a drug, provided a gradual and prolonged 
release profile compared to an aqueous drug solution of the salt form (Pignatello et 
al., 2002). The nanocrystal suspensions both improved the ophthalmic drug 
absorption and increase the intensity and duration of the drug action (Figure 6c). 
 
 
 
Figure 6 Ocular drug delivery. (A) Precorneal factors that influence bioavailability 
of topically applied ophthalmic drugs, (B) simplified ocular pharmacokinetic model 
describing the movement of a topically applied drug to the eye, (C) intraocular 
pressure of rabbits eyes following administration of hydrocortisone (Hc) solution 
and Hc nanosuspensions (NS) produced by wet milling and precipitation methods 
(modified after Kaur and Kanwar, 2002;Ali et al., 2011;Patel et al., 2013). 
 
Kinetically, corneal absorption is a much slower process than elimination (Kaur 
and Kanwar, 2002). Figure 6b presents a simplified ocular pharmacokinetic model 
describing the transfer of a topically applied drug. For most drugs Kloss is 
approximately 0.5–0.7/min and Kabs is about 0.001/min. These rate constants control 
the fraction of the applied dose absorbed into the eye, and thus the ocular 
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bioavailability (Lee and Robinson, 1986). The Kloss can be decreased by modifying 
the ocular dosage forms and the Kabs increased by formulating ocular dosage forms 
containing lipophilic prodrugs or by adding penetration enhancers. 
Furthermore, the delivery of poorly soluble drugs, such as corticosteroids like 
budesonide or beclomethasone dipropionate, to the respiratory tract is very 
important for both the local and systemic treatment of lung related diseases. These 
drugs could however be inhaled as drug NPS. Lungs are highly perfused organs with 
an expanded surface area. Due to the lack of hepatic portal drainage, molecular 
dispersion of drug is rapidly transported into the systemic circulation with high 
efficiency (Pawar et al., 2014). The tendency of the NCs to attach to mucosal surface 
offer a beneficial prolonged residence time at the site of absorption, and thus 
increase the drug absorption (Jacobs and Müller, 2002). An undesired particle 
deposition in mouth and pharynx, and thus the local and systemic side effects can be 
avoided with NCs. The lungs deposition can be controlled via the size distribution of 
the generated NCs. Compared with microparticles, the drug is more evenly 
distributed within NPS. Recently, it has been demonstrated that pulmonary NCs 
have the ability to rival pharmacokinetics offered by intravenous administration of 
baicalin (Zhang et al., 2011). Pulmonary route thus comes across as a viable option 
for delivery of therapeutics. 
Finally, the skin is a therapeutic barrier, limiting delivery of many drugs 
(Foldvari, 2000). Success in dermal delivery depends upon the permeation of drugs 
across stratum corneum (Saunders et al., 1999;Mathur et al., 2010). Due to their 
small size, NCs are expected to pack closely to form an occlusive layer which 
hydrates the skin increasing penetration and permeation of drugs. Also, the mode of 
dermal action of nanocrystals is explained via the increased saturation solubility, 
leading to an increased concentration gradient, which subsequently promotes 
penetration into the skin (Müller et al., 2011a).  This effect may be further enhanced 
by the use of positively charged polymers as stabilizers for the drug NCs. The 
opposite charge may lead to an increased affinity of the NCs to the negatively 
charged stratum corneum. NCs have been largely utilized and applied by the 
cosmetic industry. Several cosmetic products exist in the markets, especially as 
facial creams. 
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2.3.2 Marketed NC products 
Increasing resources are applied in the development of effective solid 
nanocrystal formulations. The scale-ability, or up-scaling is essential for the future 
of the pharmaceutical development of nanocrystals. The success of any formulation 
development depends on its transferability to large scale manufacture (Raghava 
Srivalli and Mishra, 2014). In order for the up-scaling to be successful, a detailed 
characterization of process parameters, design and choice of equipment, 
development of a robust formula including effective excipients and satisfactory 
stability surveillance results, are all required (Raghava Srivalli and Mishra, 2014). 
The NC approach may benefit the companies also due to the possibility of a product 
line extension offered by the FDA for the already existing drug formulations 
(Singare et al., 2010;Raghava Srivalli and Mishra, 2014). Finally, the essential 
prerequisite for entry to the pharmaceutical market is the availability of large scale 
production methods at sufficiently low cost and simultaneously meeting the 
regulatory requirements. The existing commercially available NC products and their 
characteristics are summarized Table 1. 
Principally, the advantages of the NC technology can be applied to wide range of 
poorly soluble drugs. As presented, NC approach is not applied solely for improving 
dissolution properties, but also for facilitating sustained drug release, i.e. Invega® 
Sustenna® product. Figure 7 presents some of the particular benefits of the specific 
NC products, summarizing simultaneously the general advantages of drug NCs 
(Junghanns and Müller, 2008). Besides the already marketed products, there exist 
several products close to being marketed or in clinical trials. Information about these 
products is sparingly available due to the risks for knowledge leaks and fear of 
competitors in the pharmaceutical industry, but the following examples give an idea 
of potential future products. Products in the pipeline, at clinical phases II-III, are 
such as Semapimod®/Cytokine Pharmasciences (guanylhydrazone, TNF-α 
inhibitor), Paxeed®/Angiotech (paclitaxel, anti-inflammatory), Theralux®/Celmed 
(thymectacin, anti-cancer) and Nucryst®/Nucryst Pharmaceuticals (silver, anti-
bacterial) (Junghanns and Müller, 2008). 
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Table 1 Examples of the available drug NC products and their key characteristics (WBM = wet ball milling, HPH = high-
pressure homogenization) (modified after Junghanns and Müller, 2008;Gao et al., 2013;Möschwitzer, 2013). 
 
Product/Company API Indication Method Route Formulation Approval 
Gris-Peg®/ Novartis Griseofulvin Anti-fungal Precipitation Oral Tablet 1982 
Cesamet®/Lilly  Nabilone Anti-emetic Precipitation Oral Capsule 2005 
Verelan PM®/ Schwarz Pharma Verapamil HCl Anti-arrhythmia WBM Oral Capsule 1998 
Azopt®/Alcon  Brinzolamide Glaucoma WBM Ocular Suspension 1998 
Rapamune®/Wyeth  Sirolimus Immunosuppressant WBM Oral Tablet 2000 
FocalinXR®/Novartis  Dexmethyl-phenidate HCl Anti-psychotic WBM Oral Capsule 2001 
Avinza®/King Pharm  Morphine sulfate Anti- chronic pain WBM Oral Capsule 2002 
Ritalin LA®/Novartis  Methyl-phenidate HCl Anti-psychotic WBM Oral Capsule 2002 
Herbesser®/ Mitsubishi  
Tanabe Pharma 
Diltiazem Anti-angina WBM Oral Tablet 2002 
Zanaflex™/Acorda  Tizanidine HCl Muscle relaxant WBM Oral Capsule 2002 
Emend®/ Merck Aprepitant Anti-emetic WBM Oral Capsule 2003 
Tricor®/ Abbott  Fenofibrate Hyper-cholesterolemia WBM Oral Tablet 2004 
Megace® ES/Par Pharma Megestrol acetate Appetite stimulant WBM Oral Suspension 2005 
Naprelan®/ Wyeth Naproxen sodium Anti-inflammation WBM Oral Tablet 2006 
Theodur®/Mitsubishi Tanabe Pharma Theophylline Bronchial dilation WBM Oral Tablet, Capsule 2008 
Triglide®/Skye Pharma Fenofibrate Hyper-cholesterolemia WBM, HPH Oral Tablet 2005 
Invega Sustenna®/Johnson & 
Johnson 
Paliperidone palmitate Anti-depressant WBM, HPH Parenteral i.m. injection 2009 
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Figure 7 Summary of the benefits of drug NCs specified to certain marketed NC 
products (modified from Junghanns and Müller, 2008). 
 
Besides the products already mentioned, there are drugs such as naproxen, which 
are also being investigated for formulation as NC suspension e.g. for fast action 
onset and reduced gastric irritancy (Junghanns and Müller, 2008). However, when 
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incorporating drug NCs into a tablet in relatively high concentration (single dose 
250 mg), it requires developed formulation technology to ensure the drug release. 
Related to this, the size of a tablet should be carefully evaluated with regards to 
patient compliance. In addition to these marketed NC products, the NC technology 
facilitates evolved solutions for novel biomedical applications, covered in the 
following section. 
Finally, as earlier presented, the NCs show their versatile nature by being able to 
be utilized not solely in dissolution enhancement purpose, but also in controlled 
drug delivery. This element is discussed subsequently. 
2.3.3 Controlled delivery 
In order to provide a broader perspective about the NC approach within the field 
of pharmaceutics, the subject is here widened also to other biomedical applications 
benefiting from the technology. Nanotechnology, including nanocrystals, offers 
numerous opportunities for pharmaceutical applications. Besides drug therapy, 
nanotechnology facilitates solutions for diagnostic and imaging purposes. Imaging is 
an important factor in early detection of diseases. 
The simple structural aspects of NCs allow them to be applied in controlled drug 
delivery systems facilitating i.e. sustained drug release, which is a great advantage. 
For instance highly porous nanocellulose aerogels were introduced as NC reservoirs 
for oral drug delivery systems (Valo et al., 2013). Since the release of the drug was 
controlled by the structure and interactions between the NCs and the cellulose 
matrix, modulation of the matrix formers enabled a control of the drug release rate. 
As carriers for controlled drug delivery these nanocomposite systems can facilitate 
novel possibilities for NC applications. A well-known, marketed NC product, 
Invega® Sustenna®, showing established sustained drug release profile, is a good 
example about other than dissolution related, profitable nature of drug NCs (Section 
2.3.2, Marketed NC Products).  
Furthermore, applications like magnetic nanoparticles and nanowires can be 
utilized for instance in biosensing purposes (Reiss et al., 2005;Wang et al., 2005a) 
and intracellular drug and gene delivery (Salem et al., 2004;Salem et al., 2005). 
Magnetic targeting approach provides solutions for both nucleic acid and localized 
drug delivery (Scherer et al., 2002;Schillinger et al., 2005). Together with molecular 
targeting, the magnetic nanoparticle technology has especially empowered appealing 
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approaches to early cancer detection, imaging and treatment (Romanus et al., 
2002;Brannon-Peppas and Blanchette, 2004). Moreover, NCs can also solely be 
employed for targeting purposes. Targeting ligands or other functionalizing groups 
can be incorporated on the NC surfaces. This way the NCs can be attached onto 
different matrix structures or targeted into a specific, desired site of action. For 
example a hydrophobin fusion protein, where the hydrophobin was coupled with 
two cellulose binding domains, was utilized in order to facilitate drug nanoparticle 
binding to nanofibrillar cellulose (Valo et al., 2011). The functionalized protein 
coated itraconazole nanoparticles were enclosed to this external nanofibrillar 
cellulose matrix, which provided protection for nanoparticles during the formulation 
process and storage. The versatility of NCs and ease of commercial production 
enables the development of commercially viable NPS for targeted drug delivery. 
Another interesting application to provide significant solutions for drug delivery 
and other biomedical applications are the nanogel systems, gel macromolecules in 
the size range of tens to hundreds of nanometers, loaded with different types of 
therapeutics (Yallapu et al., 2007). Nanogels are in special interest due to their slow 
degradation nature, biocompatibility, stimuli-reactiveness (e.g. pH- or temperature-
sensitive) and the ability to develop targeted drug delivery systems by surface 
functionalization.  
Numerous medical applications of gold nanoparticles are enabled due to their 
biocompatibility, dimensions and ease of characterization (Daniel and Astruc, 2004). 
Application of targeted gold nanoparticles has gained success within both detection 
and therapy of different diseases, especially within cancer treatment. As imaging 
agents, due to their photophysical properties, they offer technologies like computer 
tomography, optical coherence and photoacoustic tomography. Whereas therapy 
wise photothermal therapy, i.e. hyperthermia, and X-ray- and radiotherapy are 
facilitated, mostly utilized in cancer treatment. In conclusion, it is clear that 
nanotechnology will have a major impact on the future of novel imaging and 
therapeutic systems fighting against diseases including cancer. 
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3 Aims of the study 
The aim of this thesis was to obtain detailed knowledge about the dissolution 
characteristics of drug nanocrystals and to study the applicability of the nanocrystal 
approach for different drug delivery formulations. 
 
The specific objectives of this study were: 
 
1. To assess the effect of different nanocrystal particle size fractions to the 
dissolution behavior. Thus, the real-time, spatially and temporally resolved, 
dissolution behavior of nanocrystals was investigated using UV-Vis 
spectroscopy and a novel UV imaging technique (I). 
 
2. By utilizing the wet milling technique, to develop nanocrystal formulation to 
be administered as a suspension. This was carried out by preparing ocular, 
intraocular pressure reducing, nanocrystal formulations, whose effect was 
investigated with an in vivo ocular hypertension model (II). 
 
3. To examine formulation approaches for solid oral nanocrystal formulations, 
prepared by the rapid wet milling technique, and to evaluate their 
bioavailability in vivo (III). 
 
4. To increase the batch size of a wet milling process producing nanocrystal 
suspensions, and to screen and to optimize parameters for feasible 
nanocrystal compositions in tablet formulation (IV). 
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4 Experimental 
 Complete experimental details are reported in the original publications (I-IV). 
4.1 Materials 
Model compounds and excipients used in this work are summarized together 
with their essential properties or functions in the formulations in Table 2. The 
corresponding publications are referred to accordingly. 
 
Table 2a Model compounds used in this work (I-IV). 
API Solubility 
in aqueous media 
Molecular 
weight 
(g/mol) 
pKa Reference 
Indomethacin 
(IND) 
5 μg/ml pH=4 
14 μg/ml pH=5 
3540 μg/ml pH=7.6 
357.8 4.4 I, IV 
(Jain, 2008) 
Itraconazole 
(ITC) 
1 ng/ml pH=7 
4 μg/ml pH=1 
705.6 3.7 III, IV 
(Peeters et al., 
2002;Ghazal et 
al., 2009) 
Brinzolamide 
(BRA) 
9000 µg/ml  pH=5 
500 µg/ml pH=7.4 
383.5 5.9/8.4 II 
(DeSantis, 2000) 
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Table 2b Stabilizers and other excipients used in this work (I-IV). 
 
Excipient Function in formulation Reference 
Poloxamer 188 (F68) Stabilizer I, II, IV 
Poloxamer 407 (F127) Stabilizer I, II, III, IV 
Polysorbate 80 Stabilizer, Absorption enhancer I, II 
Hydroxypropyl methylcellulose 
(HPMC) 
Stabilizer II 
Benzalkonium chloride (BAC) Preservative II 
Microcrystalline cellulose  
(MCC; PH-101, PH-102) 
Filler I, III, IV 
Silicified microcrystalline 
cellulose (SMCC) 
Filler IV 
Lactose monohydrate 
(200M, 80M) 
Filler I, III, IV 
Polyvinylpyrrolidone (PVP) Binder III, IV 
Cross-linked-PVP Disintegrant III, IV 
Colloidal silicon dioxide (CSD) Mass lubricant III, IV 
Magnesium stearate Mould lubricant III, IV 
4.2 Production techniques 
4.2.1 Nanocrystal suspensions (I-IV) 
The starting point for this thesis was to produce NPS with wet media milling 
method. Thus, indomethacin (IND), brinzolamide (BRA) and itraconazole (ITC) 
nanocrystal suspensions (NPSs) were prepared using a rapid top-down wet milling 
technique. Stabilizer (25-80 w/w% in relation to drug amount) was dissolved in 
milling medium (5-22 ml) and, thereafter, drug powder (1-8 g) was dispersed in the 
stabilizer solution. The drug dispersion was inserted into a milling vessel (zirconium 
oxide or stainless steel) containing the maximum, varying amount of milling pearls 
(zirconium oxide or stainless steel), depending of the size of the pearls (Ø 1, 5 or 10 
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mm) and the vessel (V=20, 40 or 80 ml) used. Milling bowl was placed in a 
planetary ball mill (Pulverisette 6 (80 ml vessel, stainless steel) (IV) or Pulverisette 
7 Premium (20-40 ml vessels, zirconium oxide) (I-III), Fritsch Co., Idar-Oberstein, 
Germany) using an appropriate counter balance. Milling was performed in 3-6 min 
cycles repeated in total 6-10 times. After each cycle there was a 15 min pause for the 
system to cool down. The grinding speed was adjusted according to the milling pearl 
size (Ø 1 mm, 5 mm or 10 mm corresponded to 1100 rpm, 600 (max. for 
Pulverisette 6)/1000 rpm or 850 rpm, respectively). After milling, the NPS was 
separated from the pearls by pipetting or sieving. Detailed milling protocols for each 
of the model compounds are presented in the original publications (I-IV). 
4.2.2 Formulation of NPS (I-IV) 
After obtaining the NPS, the further formulation of the NPS was to follow. Three 
brinzolamide (BRA) NPS formulations (I-III) for ocular delivery (II) were prepared 
by diluting exact amounts of the BRA NPSs (pH=4.5 and pH=7.4), stabilized with 
HPMC (25 w/w% in relation to drug amount), with appropriate phosphate buffered 
saline (PBS, pH=4.5 or pH=7.4) solutions, including benzalkonium chloride (BAC) 
and a possible permeation enhancer (polysorbate 80) (Inoue and Shah, 2011), in a 
way that the desired formulation concentrations (BRA 1 % (w/v); HPMC 0.25 % 
(w/v); BAC 0.01 % (w/v)) were obtained. 
For both analytical (I) and formulation purposes (III, IV) the NPSs were 
transformed into solid nanocrystal powders by freeze-drying (I, III, IV) or 
granulating (III). Freeze-drying was performed either using an automatic, single 
phase 72 h freeze-drying cycle (I, III) (LyoPro 3000, Heto-Holten A/S, Allerød, 
Denmark) or a 48 h multiphase method (IV) (Lyostar II, SP Industries Inc., 
Warminster, USA). 
NC powders were formulated into both capsules (III) and tablets (III, IV) for per 
oral administration (Table 3). The NC powders could be utilized as direct 
compression (DC) tableting mass when combined with suitable tableting excipients 
(Table 2) (III, IV). Alternatively, the NCs could be processed into tablets via 
granulation. The granulation was performed either manually (III) or using a 
miniaturized, motorized mixer (Orion Pharma Oy) (IV). In order to manually 
convert the NPSs into dry powders, the NPS was used as a granulation medium in 
producing fast dissolving micro-granules. The granules were produced by manual 
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grinding using mortar, pestle and sieve. Whereas the motorized granulation process 
comprised of the miniaturized high-shear kind of wet granulation set-up, where the 
freeze-dried NC powders where sprayed with granulation fluid. In this thesis the 
tableting was performed both by manual compaction (I, III, IV) and using 
motorized, automatized (IV) mode of an instrumented (Single Station DAAS 
Measure, software version 1.2) single punch tablet press (Korsch, EK-0, Korsch, 
Germany) with rounded surface punches (Ø 9 mm and 5 mm). 
 
Table 3 The developed solid NC formulations divided according to production 
method (III, IV). 
 Tableting
1
 and 
Granulation
2
 
Process 
Drug/ NPS Excipients Reference 
Tablets 
 
DIRECT 
COMPRESSION 
 
 
manual
,1 
automated 
1 
 
 
 
automated 
1
 
 
Freeze-dried 
ITC 
 
 
 
Freeze-dried 
IND 
lactose monohydrate,  
MCC, PVP, CSD, 
cross-linked PVP,  
magnesium stearate 
 
lactose monohydrate,  
MCC, PVP, CSD, 
cross-linked PVP,  
magnesium stearate 
III, IV 
 
 
 
 
IV 
Tablets 
 
GRANULES 
 
 
manual 
1,2 
 
 
 
 
automated 
1,2
 
Granulated ITC 
 
 
 
 
Granulated ITC 
Granulated IND 
lactose monohydrate,  
MCC, PVP, CSD, 
cross-linked PVP,  
magnesium stearate 
 
PVP, cross-linked- 
PVP, SMCC, 
magnesium stearate 
III 
 
 
 
 
IV 
Capsules  
 
 
manual 
2
 
Freeze-dried 
ITC 
 
Granulated ITC 
 
 
 
MCC, PVP 
III 
 
 
III 
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4.3 Characterization techniques 
The methods for characterization of the NCs and the developed NC formulations 
are summarized in Table 4. The suppliers of the equipment can be found in the 
original publications (I-IV). 
 
 
Table 4 The key characterization methods applied in this thesis. 
Method Function Reference 
Photon Correlation 
Spectroscopy (PCS) 
Particle size and polydispersity (PI) analysis 
of the fresh and freeze-dried NPS 
I- IV 
Differential Scanning 
Calorimetry (DSC) 
Solid state analysis, confirming the 
crystalline form of the milled material 
I-IV 
X-ray Powder Diffraction 
(XRPD) 
Solid state analysis I-IV 
Scanning Electron Microscopy 
(SEM) 
Morphology, particle size and shape I-IV 
Channel Flow Method Dissolution I (Peltonen 
et al., 2003) 
UV Imaging Dissolution I 
(Østergaard 
et al., 2010) 
Paddle Method Dissolution, according to European 
Pharmacopoeia standard 
II-IV 
HPLC assays Quantification of BRA, ITC and IND 
concentrations in vitro and in vivo 
II-IV 
Cell viability assay Cellular toxicity of BRA NC formulations II 
Ocular in vivo 
hypertension model 
Elevated intraocular pressure reducing effect 
of the BRA NC formulations 
II 
(Kalesnykas 
et al., 2007) 
Per oral in vivo model Oral administration of ITC NC formulations III 
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Average tablet mass
 
Crushing strength 
Dose variation 
True density 
Powder Flowability 
Tablet Thickness 
Disintegration 
Stability surveillance 
 
 
 
Mechanical properties of ITC and IND 
NC powders and tablets 
 
III, IV 
III, IV 
III, IV 
IV 
IV 
IV 
IV 
IV 
4.3.1 Dissolution assay 
After the determination of the quality of the prepared NCs according to particle 
size, PI, morphology and solid state form, the characterization of the dissolution 
behavior of the nanocrystalline samples had a great importance in this thesis. In the 
sense of analytical development, a channel flow method (Peltonen et al., 2003) was 
applied together with UV imaging (Østergaard et al., 2010;Boetker et al., 
2011;Østergaard et al., 2011;Ye et al., 2011) (I). In order to eliminate the effect of 
increased surface area on the dissolution testing, all the tests were performed from a 
flat surface of compressed nanocrystalline powders. Whereas the paddle method, 
according to European Pharmacopoeia standard (Erweka DT-06, Heusenstamm, 
Germany and Sotax AT7, Sotax Corporation, Horsham, England), was used to study 
the dissolution of the developed BRA, ITC and IND NC formulations (II-IV).  
In the channel flow dissolution method (I) one face of the compacted sample was 
exposed to the dissolution medium (acetate buffer, pH 5.0), which circulated by a 
peristaltic pump (medium flow rate of 8.1 ml/min, Watson-Marlow, Cornwall, UK) 
through the channel flow cell, medium reservoir and UV–Vis spectrophotometer 
(analytical wavelength 318 nm) with a flow-through cuvette (UV-1600PC, VWR 
International, Leuven, Belgium). The parts of the system were interconnected in a 
closed-loop fashion using silicone tubings. UV–Vis data was collected and analyzed 
with M. Wave Professional software (v 1.0, VWR International, Leuven, Belgium). 
Dissolution rate results were calculated as a released drug amount in time unit per 
constant area. 
Additionally, an Actipix SDI300 dissolution imaging system (I) (Figure 8) 
(Paraytec Ltd., York, UK) with an Actipix flow-through type dissolution cartridge 
(CADISS-3) was also applied with following parameters: imaging area 3.64 mm × 
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8.12 mm, pixels (7 µm × 7 µm) binned 4 × 4, pulsed Xe lamp as light source, quartz 
flow cell light path 4.0 mm and detection wavelength of 265 nm. Images were 
recorded (2.6 images per s) and analyzed with Actipix D100 software version 1.3 
(Paraytec Ltd., York, UK). The dissolution of the compacted nanocrystals was 
studied both with a solution phase (acetate buffer, pH 5.0; absence and presence of 
flow: 0.5 ml/min to 0.1 ml/min) and a gel matrix (agarose/acetate buffer, pH 5.0) as 
the dissolution medium. After measurements, the conversion of pixel intensities into 
absorbance values (A) was done using the Actipix software based on Equation 4 
(Østergaard et al., 2010): 
 
     (
       
       
)            
   
where I0, Iref, and Isig are the pixel intensity due to the dark current (electronic 
noise measured with the lamp turned off), pixel intensity measured with the 
dissolution medium in the cell (reference signal), and pixel intensity measured 
during the experiment, respectively. Thus, allowing the determination of the 
apparent IND concentration within the imaging area as a function of position and 
time. For the correct conversion of pixel intensities into analyte concentrations it is a 
premise that Beer’s law is obeyed (UV absorbance for each pixel read is within the 
linear range) and that other UV absorbing species do not interfere with the 
quantification (Østergaard et al., 2010;Østergaard et al., 2011). These preconditions 
were fulfilled on the study. 
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Figure 8 Schematic representation of the UV imaging experimental setup (modified 
after Østergaard et al., 2010). 
4.3.2 In vivo models (II-III) 
Following the in vitro characterization, two in vivo models, ocular and oral, were 
applied to prove the bioavailability of the developed NC formulations. All the 
animal experiments were approved by the Finnish National Animal Ethics 
Committee in State Provincial Office of Southern Finland. The experiments were 
conducted in accordance with the guidelines set by  the Finnish Act on Animal 
Experimentation, Statute of Animal Experimentation, other animal protection 
legislation (62/2006, 36/2006 and HE32/2005), the European Union Directive 
2010/63/EU and the European Union Commission recommendations 2007/526/EC 
(European Communities Council Directive 86/ 609/EEC). 
For the ocular in vivo hypertension model (II), ocular hypertension was induced 
unilaterally to seven-month old male Wistar rats (Harlan Laboratories B.V., Venray, 
The Netherlands) using an Iris Medical argon laser (Oculight GL, Device Optical, 
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Miami, USA) (Kalesnykas et al., 2007). The contralateral eye served as an untreated 
control. 15 hours after the laser treatment, single doses (10 µl) of each suspension 
sample were applied into the laser-treated eyes using the following treatment groups: 
(1) formulation I (n = 5 rats), (2) formulation II (n = 5), (3) formulation III (n = 6), 
(4) Azopt® (n = 6), (5) 0.9% NaCl (n = 8) and (6) non-treated group (NT, n = 6). 
The IOP-values were measured both before the administration of each sample and at 
predetermined times (7.5, 15, 30, 45, 60 min) after the administration. The samples 
were coded and administered in a blinded fashion. 
For per oral in vivo experiment (III) the investigated suspension and solid 
samples, containing 2 mg of ITC, were divided into five treatment groups: 1) ITC-
NPs (n = 6, suspension); 2) freeze dried ITC-NPs (n = 6, capsule); 3) granulated 
ITC-NPs (n = 5, capsule); 4) Sporanox® (n = 6, capsule) and 5) physical mixture   
(n = 5, suspension), which were intragastrically administered to male Sprague–
Dawley rats (Laboratory Animal Centre of the University of Oulu, Finland). Blood 
samples were drawn from saphenous vein at predetermined time points: prior (0), 30 
min, 1, 2, 3, 5, 8, 12 and 24 h after the administrations. The maximum plasma 
concentration (Cmax) and the time to reach the Cmax (tmax) for ITC and hydroxyl-ITC 
(OH-ITC), an active metabolite of ITC, were assayed using LC–MS/MS (Agilent 
Technologies, Palo Alto, CA, USA) method (Decosterd et al., 2010;Valo et al., 
2011) and further analyzed with appropriate data acquisition and quantification 
softwares (Agilent MassHunter Workstation, Agilent Technologies, Palo Alto, CA, 
USA and GraphPad Prism 5.04 for Windows, GraphPad Software Inc.). 
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5 Results and Discussion 
5.1 Benefits of NCs (I-IV) 
5.1.1 Characterization of the NCs (I-IV) 
Firstly, in order to give an overview about the quality of the developed NPS, the 
results about the key characterization results are presented in this section. The 
developed NPS are summarized in Table 5. The obtained particle sizes depend on 
e.g. the stabilizer, the amount of it, size of the used milling pearls (Ø 1, 5, 10 mm), 
milling time and used milling apparatus (Pulverisette 6 or 7)(Liu et al., 2011). With 
constant milling parameters, the smaller the pearl size, the smaller and homogenous 
particles (PI < 0.5) are produced (Müller and Jacobs, 2002;Yadav et al., 2012). 
Polydisperse particles are considered to have PI-values larger than 0.7. 
 
Table 5 The compositions (% (w/w) in relation to drug amount), average particle 
sizes and polydispercity indices (PI) of the developed IND, BRA and ITC NPSs. 
API Stabilizer  % (w/w) Particle size (nm)/PI Reference 
IND
 
F68 60 580 ± 30/0.4 ± 0.1 I 
   950 ± 190/0.8 ± 0.1  
   micronsized  
   970 ± 30/0.30 ± 0.02 IV 
IND
 
F127 60 580 ± 20/0.6 ± 0.06 I 
   740 ± 30/0.7 ± 0.2  
   micronsized  
IND
 
Polysorbate 80 60 micronsized I 
BRA
 
HPMC 25 460 ± 10/0.21 ± 0.17 II 
   530 ± 2/0.12 ± 0.02  
ITC
 
F127 80 315 ± 5/0.07 ± 0.02 III 
   550 ± 20/0.40 ± 0.04 IV 
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Media milling was proven to produce crystalline drug material (IND, ITC, BRA) 
(I-IV) according to DSC and XRPD analyses, as extensively reported also earlier 
(Liu et al., 2011;Ali et al., 2011;Sarnes et al., 2013;Sarnes et al., 2014) (Figure 9). 
Milling and freeze-drying did not induce formation of amorphous IND, ITC or BRA 
nor changes in the crystalline form, supported by the absence of glass transition or 
recrystallization events (Chamarthy and Pinal, 2008). During wet milling of 
crystalline drugs the water is acting as an inhibitor of the formation of amorphous 
material due to the reduced glass-transition temperature (Sharma et al., 2009). In 
general, the NC samples showed endothermic melting events approximately at the 
same temperatures as their bulk counterparts. However, the endothermic melting 
peaks (Tm) of the NCs showed slightly shifted and broader compared to the bulk 
materials. This size of change in Tm has been reported to be related to particle size 
reduction (Xia et al., 2010;Xu et al., 2012). Also the mixtures of materials in the 
formulations have an impact to the slightly altered melting endotherms. The lower 
peak intensities of the NC samples are reported to be derived from the presence of 
the stabilizers surrounding the particles after milling (Hecq et al., 2005). 
 
 
 
Figure 9 Solid state analysis (DSC, XRPD) of ITC (A, B) and IND (C, D) NPS 
confirming the crystalline form of the drug after wet milling and freeze-drying. 
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In addition to the PCS particle size measurements, the SEM images provided 
understanding about both the morphology and confirmed the nanosized structures of 
the different NC formulations in Figure 10, which summarizes the SEM analysis of 
ITC and IND NPS (A, D), freeze-dried NPS (B,E) and granulated NPS (C, F). 
Additionally, the morphology of BRA NPS is shown (G-H), which revealed that the 
NCs were stabilized by HPMC, seen as a mass around the crystals. Some 
crystallization of the free drug occurred during the sample preparation, which was 
evident in the images as some needle-like micronsized crystals in the images (G, H). 
Commercial BRA product, Azopt®, (I) was imaged as reference. After ensuring 
these quality characteristics of the prepared NPS, the desired dissolution properties 
were closely investigated. 
 
 
 
Figure 10 SEM images showing the typical morphological characteristics of (A-C) 
ITC and (D-F) IND NPS, freeze-dried NPS and granulated NPS, respectively. 
Additionally, the morphology of (G-H) BRA NC formulations and (I) Azopt® are 
presented. 
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5.1.2 Enhanced dissolution rate and solubility of NCs (I) 
Dissolution properties of IND were improved by preparing different sized NCs 
using rapid wet milling technique with three different stabilizers, poloxamers F68 
and F127 and polysorbate 80 (Table 5). The dissolution properties of the freeze 
dried and compacted NCs were studied using the channel flow dissolution method 
and novel UV imaging technique, used in this study for the first time in the 
dissolution testing of fast-dissolving nanoscale samples. The effect of the variation 
in the area available for dissolution was eliminated by studying even, constant 
surfaces instead of particulate samples. Thus, according to the Noyes–Whitney 
equation, the dissolution rate was affected only by the concentration gradient, which 
in turn is influenced by the small particle size and the decreased diffusion layer 
thickness of the NCs. The channel flow method distinguished clearly both the 
particle size fractions and the used stabilizers (Figure 11). 
 
Figure 11 Channel flow method: dissolution of IND from the NC compacts. 
Micronsized bulk IND samples were used as corresponding references. Dissolution 
rate decreases along increasing particle size according to the arrows. 
In addition to supporting the results from the channel flow method about the 
increased dissolution rate of the NCs, UV imaging provided valuable new 
information about the concentration of the dissolved drug next to the sample surface 
(Figure 12): with the smallest NCs the concentration next to the particle surface 
exceeded fivefold the thermodynamic solubility. The apparent IND solubilities are 
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presented in Table 6 for supporting the data interpretation. This indicates that the 
solubility improvement itself, and not only the increased dissolution area, has a 
crucial role in higher dissolution rates of NC formulations. Even the micronsized 
particles showed substantially faster dissolution than the bulk material. Hence, it is 
clear that different nanocrystal size fractions provide divergent dissolution profiles. 
Based on this study it was evident that UV imaging is a promising technique to 
analyze the dissolution properties of nanoscale formulations in detail. 
 
Table 6 The effect of stabilizer (stabilizer:drug ratio 0.6:1, the total concentration 
of stabilizer being 0.5 mg/ml) on the apparent solubility of bulk IND in acetate 
buffer (pH 5.0, after 12 h of shaking, n=3, T = 19-22°C ). 
Composition Solubility   
 μg/ml mM 
IND/F68 6.43 ± 0.06 0.018 ± 0.00 
IND/F127 4.80 ± 0.00 0.013 ± 0.00 
IND/polysorbate 80 10.9 ± 1.54 0.030 ± 0.00 
Bulk IND 4.89 ± 0.18  0.014 ± 0.001 
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Figure 12 Apparent concentration-distance profiles obtained from UV imaging of 
IND NCs at time points 5, 15 and 30 min: (A) F68/580 ± 30 nm, (B) 
F68/micronsized particles, (C) F127/580 ± 20 nm, (D) F127/micronsized particles 
and (E) bulk IND/tens of µm. 
5.2 NC Suspension formulation (II) 
The beneficial character of NCs was next aimed to be utilized in formulation 
development. Three ophthalmic BRA NC formulations (BRA, 16 w/w%) in PBS 
(pH 4.5 and 7.4), stabilized with HPMC, were successfully developed using the 
straightforward rapid wet media-milling technique (Table 7). In addition to the 
beneficial characteristics of HPMC, such as low toxicity, prolonged contact with the 
mucosa and, most of all, its highly swellable nature (Toda et al., 1996;Ludwig, 
2005;El-Sousi et al., 2013), HPMC is also approved for ocular drug delivery as an 
inactive ingredient, and has been used as an ophthalmic lubricant and tear substitute 
(FDA;El-Sousi et al., 2013). Polysorbate 80 was added after the milling to 
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formulation II because of the well-known permeation enhancing effect in ocular 
drug delivery (Kaur and Kanwar, 2002;Inoue et al., 2006). The pH values were 
selected in order to study the importance of the free drug amount for the efficacy of 
the formulations. The aqueous phase of the NC suspensions was saturated with the 
drug, and with BRA, the solubility at pH 4.5 was considerably higher when 
compared the situation at pH 7.4. An acidic pH increases the solubility of the 
ampholytic BRA (pKa 5.9/amine, 8.4/primary sulfonamide) compared to its 
solubility at physiological pH, where the drug is significantly less protonated; the 
solubility of BRA increases from 0.4 mg/ml (pH 7.4) to >30 mg/ml (pH 3.8) (Hall et 
al., 1999). 
 
Table 7 The properties (n=3) of the prepared BRA nanocrystal formulations (I-III) 
and the negative control (BRA, 1 w/v%; HPMC 0.25 w/v%; BAC, 0.01 w/v%). 
 Composition Particle size 
(nm) 
PI 
Formulation I BRA-NPs
a
, pH 7.4 460 ± 10 0.21 ± 0.17 
  
BAC 
PBS, pH 7.4  
 
Formulation II BRA-NPs
a
, pH 7.4 460 ± 10 0.21 ± 0.17 
  
Polysorbate 80  
(0.25 w/v%) 
 
 
  
BAC 
PBS, pH 7.4  
 
Formulation III BRA-NPs
a
, pH 4.5 530 ± 2 0.12 ± 0.02 
  
BAC 
PBS, pH 4.5 
 
 
Negative control
b
, bulk BRA micronized
c
  
in vitro HPMC   
  
BAC 
PBS, pH 7.4  
 
(
a
BRA; 16 % ( w/w), 
 b
physical mixture, 
c
particle size > 10 µm, outside the PCS detection limits) 
 
The ophthalmic NPS formulations (I–III) dissolved immediately in vitro in PBS 
pH 7.4 (Figure 13a.). Neither the pH 4.5 (formulation III) nor the added solubilizing 
agent, polysorbate 80 (formulation II), had any major influence on the dissolution 
profiles. 
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The laser treatment was successfully performed based on the mean IOP values of 
the treated (39.6 ± 2.7 mmHg) and contralateral control eyes (10.8 ± 0.2 mmHg) 
(independent samples t-test, P ≤ 0.001). The in vivo rat ocular hypertension model 
showed the significantly decreased intraocular pressure values by all the 
formulations (Figure 13b). The IOP reduction was enhanced at pH 4.5, when the 
free drug in the NPS (formulation III) was at its highest. The acidic pH improves 
BRA solubility excessively when compared to the neutral pH (Hall et al., 1999). The 
low pH of formulation III was able to facilitate an advantageous IOP response even 
though the unionized form of a drug, present at pH 7.4 for BRA does favor the 
ocular absorption (Järvinen et al., 1994). This can be explained by the fact that acids 
tend to become buffered in the eye. The greatest relative IOP reduction (72.2%) was 
observed with formulation III at 45 min after administration. The actions of the 
formulations were proven against the commercial BRA product, Azopt®, used as a 
control. In conclusion, formulation III reduced IOP after 60 min more effectively 
than formulation II (P = 0.017) and Azopt® (P = 0.004), whereas the difference to 
formulation I was insignificant (P = 0.126). The results revealed that NPS are valid 
tools for ophthalmic drug delivery and valid therapeutic approaches. 
 
 
 
Figure 13 (A) The in vitro dissolution profiles of BRA NPS formulations (I-III), 
Azopt® and negative control in PBS pH 7.4 using the paddle method. (B) The 
elevated IOP reducing effect of the same samples (NT, non-treated group). 
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5.3 Solid NC Formulation (III-IV) 
5.3.1  Superior in vitro dissolution – Absence of in vivo correlation             
(III, Supplement I) 
As presented, solid dosage form is generally preferred in drug delivery. Hence, 
itraconazole (ITC) nanocrystal suspensions, prepared by media milling (section 
5.1.1, Table 5) were transformed into solid form by both freeze drying and 
granulation, and further developed both into tablets (25 mg; 1.2 mg ITC, 40 N) and 
capsules (25 mg; 1 mg ITC). The freeze dried ITC formulation proved to be equally 
advantageous as the NC suspension formulation according to both in vitro 
dissolution and in vivo bioavailability analyses (Figure 14a). Even after a 
compaction process of both freeze-dried and granulated NC suspensions, the rapid in 
vitro dissolution characteristics were maintained. The solid ITC NC formulations 
were in vitro superior to Sporanox® capsules, a marketed itraconazole product, 
which was used as a reference. 
Tablet formulations were excluded from the in vivo experiments due to their 
large size and thus unreliable dosing to the rats. Additionally, the dosage form was 
different. Thus, the ITC-NPS and capsulated freeze-dried and granulated NPSs were 
administered to the rats (Section 4.3.2). When the in vivo bioavailability was 
compared, however, Sporanox® capsules significantly outperformed all the NC 
formulations (Figure 14b-c). This unexpected result indicates the difficulty to predict 
the in vivo behavior on the basis of the in vitro analyses: superior in vitro dissolution 
enhancement was not realized in in vivo drug absorption. In this particular case, the 
sugar beads in the Sporanox® formulation (Kapsi and Ayres, 2001) may have 
prolonged its retention time in the stomach, where ITC is dissolved slowly and 
emptied into the intestine for enhanced absorption. On the other hand, the ITC 
nanocrystal formulations may have passed through the stomach rapidly like a liquid 
formulation due to increased dissolution. The solubility of ITC is considerably much 
lower in the intestine than in the stomach, and thus, the high concentration of ITC 
from NCs may have precipitated in the small intestine (Van Speybroeck et al., 
2010). The peak drug concentration of the freeze dried formulation occurred in the 
first minutes (Figure 14b), indicating rapid dissolution, followed by precipitation in 
the intestine. An efficient way to deliver ITC may be to facilitate rapid highly 
concentrated solution in the stomach and stabilize the solution when entering the 
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small intestine. The stomach serves thus as a reservoir, from which the highly 
concentrated solution ITC can be delivered to the small intestine, and to be absorbed 
(Matteucci et al., 2009). Matrix type of structures, utilized for instance in 
Sporanox®, which remain longer times in the stomach, could be applied here in 
wider sense. Because of this unique behavior of ITC in the gastrointestinal tract, I ts 
in vivo behavior could not be predicted on the basis of the in vitro analysis. 
 
 
Figure 14 (A) The in vitro dissolution profiles of the ITC NC formulations, and in 
vivo pharmacokinetic profiles of (B) ITC and (C) its active metabolite, OH-ITC, 
after per oral administration of the NC formulations. 
Despite the fact that the NC formulations did not exhibit advantageous in vivo 
behavior in comparison to the marketed product, the results provided valuable 
information and starting points in order to further improve the in vivo 
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pharmacokinetics of ITC with the NC approach. For the further formulation 
research, there exists a need to obtain detailed information about the reasons 
explaining the in vivo advantageousness of Sporanox®. Especially the solubilization 
and precipitation inhibition as well as the stabilized supersaturation are mechanisms 
that are to be closely investigated.  There may be many other drugs that show similar 
behavior as ITC. This may be one of the reasons why only a very small number of 
clinically used nanocrystal formulations have been developed. Each drug may have 
to be analyzed differently based on its pH-dependent solubility. If a drug is less 
soluble in the intestine, rapid dissolution in the stomach may not increase the 
bioavailability. For the drugs like ITC having pH-dependent solubility and the drugs 
having a window for absorption, prolonged retention in the stomach may be as 
important as improving the drug solubility. It is vital to consider various formulation 
parameters carefully to develop clinically useful formulations, rather than relying on 
a single parameter such as water solubility alone. Finally, these tools could be 
combined with the nanocrystal approach and hopefully utilized to offer a valuable 
approach for delivering poorly soluble drugs like ITC. 
5.3.2 Feasibility of NC approach for tableting applications (IV) 
Finally, the concept of solid NC formulation was further processed in order to 
expand the knowledge for higher amounts of NC formulations. Thus, ITC and IND 
NPSs were successfully manufactured by wet milling, increasing the batch scale 2-4 
times, freeze-dried, and further developed into both direct compression (DC1-DC3) 
and granulated (G) tableting masses (Table 8). In order to find the optimal 
formulations for tableting, the powder and tablet properties of the ITC and IND, 
both DC and G compositions, were screened and compared in detail according to 
true density, powder flowability, dose uniformity, maximum upper punch force, 
tablet crushing strength, dissolution and disintegration behavior, and stability 
testings. 
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Table 8 The compositions of test formulae (% w/w) of the ITC and IND NC 
formulations for direct compression (ITC; DC1, DC2, DC3 // IND; DC1, DC2, 
DC3), the final ITC and IND DC compositions (fDC), the ITC (ITCG) and IND 
(INDG) NC granulation formulas for 250 mg tablets, and the physical mixtures 
(PM). 
Composition 
(w/w%) 
DC1
a 
 DC2  DC3  ITCG
a
 INDG
a
 
ITC IND
b,c
 ITC
c 
IND
b
 ITC
b
 IND
b
   
Freeze-dried NPS 
 
18 40
 
40 60
 
 71 75 73 57 
MCC 41 29 29 19 11 9   
Lactose 
monohydrate 
30 20 20 10 7 5   
PVP 5 5 5 5 5 5 3 3 
cross-linked PVP 5 5 5 5 5 5 5 5 
CSD 0.5 0.5 0.5 0.5 0.5 0.5   
SMCC       18.5 34.5 
Magnesium 
stearate 
stalllstearate 
sstestearate 
0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
(
a
PMs, NPS replaced with bulk ITC/IND, 
b
Therapeutic dose included, 
c
fDC compositions.) 
 
The critical tableting parameters were optimized by manually compacting both 
ITC and IND DC1-DC3 compositions and PMs (n = approx. 30 tablets), whereas the 
G and fDC compositions were compressed using the automated process (n = approx. 
300 tablets), which explains the differences in the forces and in the comparisons 
made in the data analysis. The tableting experiments with the ITC and IND DC1-
DC3 compositions demonstrated informatively the effect of the varying amounts of 
NC powders. The existence of NCs improved the compressibility; with lower force, 
sufficiently hard tablets were provided. Figure 15 shows intriguing information 
about the compression force and tablet crushing strength with different 
compositions. An important factor explaining the results is the particle size. The 
smaller the particle size, the more there exists contact surfaces, and thus the greatest 
potential for bond formation, which in turn increases the hardness, i.e. crushing 
strength, of the tablets (MCKennan and MCCafferty, 1982;Velasco et al., 1999). 
The increased number of contact surfaces and thus potential for bond formation 
explains the fact that the greater the load of nanocrystals in the composition, the 
lower force is required to produce hard tablets. Both the granulated compositions, 
Results and Discussion 
 
 
 
53 
 
ITC G and IND G, facilitated significantly harder tablets, compared to the final ITC 
DC (P < 0.001 ) and IND DC compositions (P < 0.0001), with  lower forces (P < 
0.0001). This supports the well-known profitable properties of granulated tableting 
masses (Iveson et al., 2001), which can be compressed more easily and consume less 
energy (Faure et al., 2001;Hansuld and Briens, 2014). 
 
 
 
 
Figure 15 The maximum upper punch forces (N, column) with each (A) ITC and (B) 
IND compositions (DC1-DC3, final (f) DC, G, PM) in comparison to the average 
crushing strengths (N, after 48 h from tableting, line) of the compressed 250 mg 
tablets. 
Furthermore, the dissolution behavior of IND was dependent on the load of 
nanocrystal powder in the IND DC1-DC3 tablet formulations (Figure 16a). At 15 
min detection time-point the released drug load from the IND DC1 tablets was 
clearly higher than from the DC2 and DC3 tablets (P < 0.0001). The drug release 
from DC2 was in turn significantly above DC3 tablets (P < 0.05). Taking into 
account the tablet properties, processablity, inclusion of adequate drug 
concentrations and dissolution profiles, the IND DC1 showed to be the best 
candidate for the final DC formula. ITC DC1 mini-tablets (30 mg) enabled the ITC 
dissolution study in sink-conditions, and thus related the ITC dissolution to its 
disintegration behavior. This relation between disintegration and dissolution was 
utilized to describe the dissolution behavior of the highly concentrated ITC DC2 and 
DC3 tablets, which were otherwise excluded from the dissolution analyses due to the 
high drug content. 
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Figure 16 The dissolution profiles of (A) IND DC1-DC3 tablets (250 mg) and 
powders, (B) IND NPS compared to final IND DC (fDC), G and PM tablets (250 
mg), and (C) ITC NPS compared to DC1 tablets (30 mg) and powder and PM 
tablets (30mg). 
The disintegration results demonstrated also the effect of the amount of 
nanocrystal powders in the tablets ( Figure 17): the less the formulation included 
nanocrystal powder (ITC DC1 // IND DC1), thus the more porous and less dense the 
structure, the faster was the medium penetration (diffusion), and the tablet 
disintegration. ITC and IND DC2s, and moreover the DC3s, provided more 
prolonged medium diffusion times. The disintegration times correlated in general 
well with the crushing strength values. The compositions of both the model 
substances showed comparable disintegration behavior in descending order 
according to the disintegration times (DC3 > DC2 > DC1 > PM and G > fDC, P ≤ 
0.001). The disintegration results proposed the choice of ITC DC2 and IND DC1 for 
the final DC compositions. ITC DC2 offered the most suitable choice, since it 
provided an opportunity of inclusion of adequate drug concentrations in reasonable 
sized tablets, which would be disintegrated within acceptable time frames. 
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 Figure 17 The disintegration times (min, column) versus crushing strengths (N, 
line) of the (A) ITC and (B) IND tablets. 
In conclusion, the amount of the nanocrystal powder is critical for the 
formulation. When including excessive amounts of nanocrystals in the formulation, 
the benefits of the nanosized powders will be finally lost. Thus, there exists a 
maximum concentration, which provides good processability resulting in tablets 
with suitable strengths and drug release properties, i.e. dissolution behaviors and 
disintegration times. The DC designs of both the model drugs with compositions 
including 40% of freeze-dried nanocrystalline drug powder (ITC DC2 and IND 
DC1) outperformed the corresponding granulated tablets in all parameters after the 
stability surveillance. In the light of these evidences, both the model substances 
would benefit from nanocrystal tablet formulation approach. 
 
Conclusions 
 
 
 
56 
 
6 Conclusions 
Dissolution properties of the poorly soluble drugs (indomethacin, brinzolamide, 
itraconazole) were improved by preparing drug nanocrystals with universally 
applicable and industrially relevant, rapid wet media milling technique. High-quality 
nanocrystal suspensions, regarding particle size, size uniformity, morphology, 
stability and solid state were obtained. Dissolution study of freeze-dried nanocrystal 
compacts with the channel flow dissolution method and the novel UV imaging 
technique revealed the significance of the particle size for dissolution. UV imaging 
provided valuable new information about the concentration of the dissolved drug 
next to the sample surface: with the smallest nanocrystals the concentration next to 
the particle surface exceeded five-fold the thermodynamic solubility, creating 
supersaturated states. Even though the effect of the variation in the area available for 
dissolution was eliminated by studying smooth, constant surfaces instead of 
particulate samples, the differences between particle sizes were evident. This 
difference will be increased even further in actual drug formulation. This indicates 
that the solubility improvement itself, and not only the increased dissolution area, 
have a crucial role in higher dissolution rates of nanocrystal formulations. 
Three ophthalmic BRA nanocrystal suspension formulations in PBS (pH 4.5 and 
7.4) were successfully developed using HPMC as an effective stabilizer. The 
ophthalmic nanocrystal suspensions dissolved immediately in vitro and were 
homogenous and stable. The in vivo rat ocular hypertension model showed the 
significantly decreased intraocular pressure values by all the formulations. The IOP 
reduction was enhanced the most at pH 4.5, when the amount of free drug in the 
nanosuspension (formulation III) was at its highest. The actions of the formulations 
were proven against the commercial BRA product used as a control. The results 
revealed that nanocrystal suspensions are valid tools for ophthalmic drug delivery 
and therapeutic approaches. 
Lastly, the results of the set of performed experiments answered to a wide range 
of questions regarding the feasibility and the preparation of solid oral nanocrystal 
formulations. Freeze-drying was proven over granulation to be an effective method 
to convert the nanocrystal suspension into dry powders. The compaction process of 
nanocrystal powders was performed successfully, maintaining the original 
characteristics of the nanocrystals, i.e. rapid dissolution. The up-scaling of wet 
milling was a straightforward process, and regarding the further formulation 
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development, it was clear that the amount of the nanocrystal powder in the solid 
formulation was critical in order to be able to fully utilize the benefits of the 
nanocrystals. Therefore, nanocrystal tablet formulation is an advantageous design 
with a fairly simple production process. However, the difficulty to predict the in vivo 
behavior on the basis of the in vitro analyses was demonstrated.  
To conclude, NC suspensions offers a versatile platform to deliver poorly water 
soluble drugs via liquid and solid formulation. However, the formulation should be 
carefully considered in order to obtain an in vitro-in vivo correlation and, thus the 
transfer of the in vitro benefits to an in vivo environment. 
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